S Ritland - Concepedia

Author

S Ritland

Mayo Clinic

Also Known As

S R Ritland, S Ritland, S. Ritland, STEVE R. RITLAND, STEVE RITLAND, Steve R. Ritland, Steve Ritland

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Arizona Rutgers New Jersey Medical School La Roche College

About

S Ritland is an author at Mayo Clinic specializing in medicine, oncology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	914
2	Immunology	5	5	241
3	Health Sciences	2	2	218
4	Cell Biology	2	2	65
5	Gastroenterology	2	2	139

S Ritland

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Human epithelial ovarian cancer allelotype. William A. Cliby, S Ritland, Lynn C. Hartmann, PubMed Regional DeletionTumor BiologyPolymorphic MarkersTumoral PathologyTumor Heterogeneity	1993	242
Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas David Ransom, S Ritland, David W. Kimmel, Genes Chromosomes and Cancer	1992	181
Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers. Marie A. Herrmann, Ian Hay, Duane H. Bartelt, Journal of Clinical Investigation Cancer PathologyMolecular Genetic StudiesCytogeneticsMedicineGenetics	1991	138
Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Satoru Takahashi, Ailin Shan, S Ritland, PubMed CytogeneticsGeneticsAllelic ImbalancesPathologyTumor Biology	1995	121
A Selective Phosphatase of Regenerating Liver Phosphatase Inhibitor Suppresses Tumor Cell Anchorage-Independent Growth by a Novel Mechanism Involving p130Cas Cleavage Sherif Daouti, Wen Hui Li, Hong Qian, Cancer Research	2008	98
Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Mark K. Dodson, Lynn C. Hartmann, William A. Cliby, PubMed Polymorphism AnalysisTumoral PathologyCancer PathologyTumor HeterogeneityCytogenetics	1993	97
Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression S Ritland, Sandra Gendler Carcinogenesis Chemoprevention StrategyImmunologyGastroenterologyPathologyDigestive Tract	1999	96
Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis. Gerald J. Rowse, S Ritland, Sandra Gendler PubMed Latency EquivalentBreast OncologyEndocrine-related CancerOncogenic AgentLatency Effect	1998	55
Aggressive Medulloblastoma With High-Level N-myc Amplification Francis H. Tomlinson, Robert B. Jenkins, Bernd W. Scheithauer, Mayo Clinic Proceedings Neuro-oncologyMedicineHistopathologyPathologyHigh-level N-myc Amplification	1994	51
Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. S Ritland, Jonathan A. Leighton, Rhoda Elison Hirsch, PubMed Chemoprevention StrategyPolyp NumberImmunologyGastroenterologyPharmacotherapy	1999	43

Page 1